{
    "filename": "CPG Childhood Immunisation.pdf",
    "metadata": {
        "format": "PDF 1.6",
        "title": "",
        "author": "",
        "subject": "",
        "keywords": "",
        "creator": "Adobe Acrobat 7.0",
        "producer": "Adobe Acrobat 7.0 Image Conversion Plug-in",
        "creationDate": "D:20060322162231+08'00'",
        "modDate": "D:20060322162231+08'00'",
        "trapped": "",
        "encryption": null
    },
    "total_pages": 36,
    "pages": [
        {
            "page_number": 1,
            "text": "CLINICAL PRACTICE GUIDELINES\n\nCHILDHOOD IMMUNISATION",
            "extraction_method": "ocr"
        },
        {
            "page_number": 2,
            "text": "‘Ths gudetine smear to be gue for cnc pact, based on the best vale\nevicence a the time of development. Adherence to this guideline may not\nessay entre the best outcome In every cata Every heath cate prover Ie\nrespon forthe management of hive unique patient based on the cia\nPc preserte byte patarit anl the managerent options ave oal\n\nThs gute was ised in September 204 and wel be reviewed in September\nes orsooner# new dence Dec wala.\n\nrs Secreta\n‘oven Techeology Assessment Unt\nHedcal Developme Dison\nMossy of Heath asi\n\n2s Flo Bangunan AKA\nJatpos\n\nSi200 cata Lumpur\n\nabla teflon bie ip worumah ou\nwtp wacom agar",
            "extraction_method": "ocr"
        },
        {
            "page_number": 3,
            "text": "GUIDELINES DEVELOPMENT AND OBJECTIVES.\n\nGuideline Development\nThe work gioup fr the dovelopment of tose gudaines comprised\npaodatcians fom various Minty of Heal facies. These gues\nSe based onthe fodings of health ectinlogy orsosemant on he sae\n‘opi, 25 wel as a systematic review of caert medial Herat. The\n‘ranking of exdonoe Is Daned on modified vrson of fat suggested by\nthe Catalonia Agency for Hoan Tocmncogy Assessment nd Research\n(CANTAR) Spain, while the grading of recommendations in those\n‘uldetnss emulates that wed by the Scotian Inaycomgiat» Gudanos\nNetwot (SIGN). The daft gudalines were posted on both the Niniy\n‘of Heat Malaysia and Academy of Medicine, Malaysia wobste for\nomment and feedback. Those guidlines have also been presented ©\nthe Technical Advsory Commitee for Clsical Pract Gudolines ane\nHealth Tecmsology Assossmont and Canal Pracice Guselnes\n(Counes, Misty of Heath Milaysia fr review and approval\n\nObjective\n‘Tho aim of his gin is oa heath caro providers in gonora\nraces and pedatcians, in cdl decison making by providing wall\nEstanesd evidence bated infmaton on chikdhod emanieaton Ilsa\nhoped to doctease he ncilence of compicatona.\n\n“Target Population\n“This guideline Is dovoloped to apply oa chron,\n\n‘Target Group\nThis guideline fs meant for a heath care proves,",
            "extraction_method": "ocr"
        },
        {
            "page_number": 4,
            "text": "ithod inaiston\n\nLEVEL OF EVIDENCE SCALE\n‘Strength of ‘Study design\nlevsance,\nGood TORT, Systema Tovow\n\nine Good | Large ameio RET\nL\n\n7 Sia sanelo ROT\nI 00d 0 Fair\n\nfa Non andonised conoied prospective Wal\n\nTon andonised convaied prospec Wal wit\n\nato! control\nD Far] Cott uo\n7 Poor] Case conta ataios\n: Poor | NERO i, ec\nExpat Somos, consensus, cava ropa,\n® Poor | anecdotes\n(Raiied Fam, Caan Aa Tr Fat Toslay Resse &\nRescorch,(CAHTARY Soa)\nGRADE OF RECOMMENDATIONS\n\nToast one meta analysis, systemate review, of RCT, or ovdence\na good and érectyappleabl te he rget popuation\n\n1p Fence rm well condcted cine inal, drocy applicable othe\nPopulation, and demonstrating vera constancy of resis:\noxtapoiated fom meta anal, sytem ovow, of RCT\n\n[Evidence rom exper commie parts, or oplniens and/or niet\n| © letpetiences of respect authoatos: india abaance of drecly\n| em stadlos of good ualty\n\n(Adopted tom Scots tarcdeate Guten Network (SIGND",
            "extraction_method": "ocr"
        },
        {                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
            "page_number": 5,
            "text": "sind ime\n\nGUIDELINES COMMITTEE\nDr Tan Kah Koo\n\nConstant Paediatrician\nDepartment of Poodatis\nSeremban Hospiat\n\nr Wong Smee Lan\nConsultant Paediatrician\nDeparment of Poedatics\nSorersban Hospital\n\nOr Kuan Gok Lan\nConsstant Paodaincin\nDepartment of Paediates\n‘Malacca Hesptt\n\nDr Zainah Shak Hod\nConstant Pacdatigan\nDeparment of Paedatics\nMalocea Hospital\n\nDate’ Or Jinmy Lee Kok Fo\nConstant Pacdatican\n\nDoparimort of Poetics\nKuala Terenggana Hospital\n\nDr Hang Long C00\nConstant Paesiatcian\nInatve of Paosstien\n‘ala Lumpur Hespiat\n\nDe Naat Shims\nFamby Hoa Development Division\nMoisty of Healt Malaysia",
            "extraction_method": "ocr"
        },
        {
            "page_number": 6,
            "text": "Guidelines Coordint\nMe Sin Lin Thye\nusing Stor\n\n‘oath Tecnology Assessment Unit\nMisty of Heath Naaysia\n\nead, Health Technology Assessment Unit\nDeputy Drcto,\n\nMedical Development Division\n\nintr of Heath Malaysia",
            "extraction_method": "ocr"
        },
        {
            "page_number": 7,
            "text": "‘TABLE OF CONTENTS.\n(CHILDHOOD iMMUNISATION\n\nTABLES\n\n‘able 1 EPI sehedie\n\nTable 2 New immurssatin schedule\n\nTable 3 Recommended immunsation schedule\n“Inmactoetetent crn\n\neco\n\nINTRODUCTION\nADVERSE EFFECTS:\n\n21 Md Adverse Events\n\n22 _Sovore Adverse Evens\n\nVACCINE EFFICACY\n\n'STORAGE AND ADMINISTRATION\nIMMUNISATION SCHEDULE\n\nSPECIAL SITUATIONS\n\n1 Premature and Low Binh Weight Babies\n2 Babies oem to HV postve motors\n\nDIPHTHERIA, TETANUS AND PERTUSSIS.\n4. rROQUCTION\n1 Dihiheria\n12° Totanas\n13 Parts\n14 OPT Vaccine\n2 ADVERSE EFFECTS\n24 Systemic Reactions\n3. VACCINE EFFICACY\n31 Dipiaria Vaccine\n32. Tetanus Toso Vaccine\n33 Pertussis Vaccine\n4. STORAGE. DOSAGE AND ADMINISTRATION\n41 Daphnia Vaccine\n$2 Tetanvs Toso’\n43 Pertussis Vaccine\n5 RECELERATED OTP MMUNISATION SCHEDULE\n\nPOLIOVIRUS VACCINE\nlrRooucTON\n\nADVERSE EFFECTS\n\nVACCINE EFFICACY\n\n‘STORAGE, DOSAGE AND ROUTE OF ADMINISTRATION",
            "extraction_method": "ocr"
        },
        {
            "page_number": 8,
            "text": "SCHEDULE\nSPECIAL SITUATIONS\n\nNEPATITISB VACCINE\nINTRODUCTION\n\nADVERSE EFFECTS.\n\nVACCINE EFFICACY\n\n‘STORAGE, DOSAGE AND ADMINISTRATION\n‘SPECIAL SITUATIONS\n\n5.1. Infants Bom to HosAg Positive Methors\n82) Proton want\n\n53. SerogieTestng\n\nHAEMOPHILUS INFLUENZAE VACCINE\nWwTRODUCTION\n\nADVERSE EFFECTS.\n\n‘VACCINE EFFICACY\n\nCOMBINATION OF VACCINES.\n\n‘STORAGE, DOSAGE AND ROUTE OF ADMINISTRATION\n‘SCHEDULE\n\n‘SPECIAL SITUATIONS\n\n71 Promature Babies\n\n7.2 Thaassasmia and Splonecomy\n\n73. HWVinfecson\n\nMEASLES, MUMPS AND RUBELLA VACCINE\ninTRoDUGTION\n\n11 Meas\n\n12 Mumps\n\n13° Ribot\n\n13 MMR Vaccing\n\nADVERSE EFFECTS.\n\n‘VACCINE EFFICACY\n\n‘STORAGE, DOSAGE AND ROUTE OF ADMINISTRATION\n‘SCHEDULE.\n\nSPECIAL SITUATIONS.\n\n{6.1 Measlas Immunisation in IV Infected Chien:\n6.2._Steroid Treatment\n\nREFERENCES.\n\n2\nfs\n\n5\n6\n6\n6\n\n1%\n%\n0\no\n°\n\nPEEEEDEEeEeT yy)",
            "extraction_method": "ocr"
        },
        {
            "page_number": 9,
            "text": "nnd meat\n\n‘CHILHOOD IMMUNISATION\n\nImmunisation isan attempt to roplaco the anticipated natural pimary\n“conic batwoan the human Body and a hosto organi. wt lor\nStic contact, so that any subsequent naturel contact takes place ina\nStale of hoghtoned immunity. Whlo advances in publ heath ad\n‘medicine have reduced he morbid and mortality ates accompanying\nGeran Infoctous diseases, immuntsation represents the single ost\n‘mass approach to prevention (Zimmerman, 1987)\n\nTho World Heath Organisation (WHO) Expanded Programme on\nInmunatn (EPN) recommends tat ‘| counties immunise agalnst\nDolomiti, dehera, porussis, tears, meaues, and tuberculoes\n{Te} foc in counties witha high inedncs. In ado. Hepaits 8\n“aceine was tobe inlograted to rations munsaton programm\n‘al cous by 1997 (testy of Heath Malays, 2002, ove?)\n\nTable 1; EP achadule\n\nTae ican epg 8 Varig\n‘Sone\n\naa OG, OPV\n\nSooo Der sort ves\n\ntoweoks ber 2 opv2 Kez\n\nett\n{5 vor segs fom Sth ha) tos chen 0 for Davo woh se Pee\nointl aremstn (9 Sub-saaran e)\n\n‘has generally boon accopted that no immurisatonschedula fs dea.\n‘and us tho EPI rocommands thal each courry dotmine A OMe\nSched tat bost su is needs. Tho eatoge quing principle of any\nimmunisation programme is that potecson must be achieved balore\ninfants are a high sk of @ diseaso. In most developing counties,\n‘deases lnluded wit the EPI stike gary I io, ond thus\nimportant io protct chron Beough immunisation 25 oary as possible.\n[Apt toni, any mena ached represents sem degree\nCompromise. In addon, wile acknowadging thet seroconversion =\n‘9ge-dopondont, ho omphasis shoud be on blaring protection Inthe\ninfant at as young an age as pasate (tris of Heath Malaysia, 2002,\nfave!\n\n‘Tho iemunsaton programm in Malaysia commonced about 40 years\n‘go with the OPT vaccine, Ts was fotowed by be BCS vaccine\n4961 and tho OPV vacsine a 1972. Meas enmunisaton was added",
            "extraction_method": "ocr"
        },
        {
            "page_number": 10,
            "text": "sind nme\n\n'o the programme in 1984, wih immunisation against rubella being\nInrocused i 1088 and against bepatta Bm 189 (Patnanathan,\n1300), The immunisaton coverage for Malaysia was 99.97% tor BCG,\n96.9% for OPT (hea dose}, 54% for OPV (hed dose), 88.4% for\nfmoases snd 895% for hepaits © (Bid dose) io 2000 (Misty of\nFoam Malaysia, 2002, love 1). The now recommended immunaation\n‘shod a9 tsraed in Table 2 bolow:\n\nTable 2: New immunisation schoduo\n\ni ee\n\nFor immunodefisant chien, the recommended schedule Is shown\nbelow\n\n“Table 3 Recommended Immunisation Shed frrmunodeictnt\n\n‘Chidren|\n[mimantation | Tmmunosuppresive wv | Banga\nL therapy Contacts\nBC. No.\nHep Yes\nPT Yes.\n‘OPV No\nco Yea > Boar\n\n- ose)\n| oasios wo T\n\n|\n\nor Ne T",
            "extraction_method": "ocr"
        },
        {
            "page_number": 11,
            "text": "BCG VACCINE\n4. INTRODUCTION.\n\nIn Malaysia, the incidence of tuberculosis was 63.6 por 100,000\n‘opuition i 1997, and has oon increasing stony sien 1905, Tho\n‘most important souree of human inecton fs an infected person who\n‘Spreads the high Infecous baci through respiratory dopa, Primary\n{ocsons occur at any 9, most often In chien, may ba\n_asymotomatic, and ressive spontaneousy. Homever it may also spread\nnd caso diioavo in varous organs Incuding ngs, menges. bones\n‘and Boodeteam (Minit of Hoatn Malaysia, 2002, vel 1),\n\n‘Te Bacile Calmette-Guerin (BCG) vaccine is ae attonsated stan of\nMycobactorum bovis, contaring no aduvant oF preservative excoot\n‘monssodiam glamale or atumin as the stablzer. Tho aon othat\nSaino coktion or sailed waler WHO. recommends. that bo\n‘Sdmaitored a ith and is cuendy used i more thon 100 counties\n(0, 2000 foe! 1).\n\n2. ADVERSE EFFECTS\n\nFollowing intradermal injocton, lal acon és normal, © papue\nforming win 2-3 wooks, with uation at 6.8 weeks, flowed by 2\n‘scr a tho and of 3 month, The adverse events ar precomnany\n‘elated 10 infection by be five atteruates bacea, as wl as being Ge\n{o crore in achieving ita-doomal ocuation. They ea be classed a\n‘mild and severe events and ae elaborated on 260m.\n\n2.4 Mild Adverse Events\nThe most common adverse effect of subcutanwous injection i a local\n_abscass White moro extoisve and prolonged cal veactons ca ocr,\nSncondary nfoctons atthe to of injoctons ao unlikely Somes,\nSry or coral fymphadenits may develop. However. n most casos\nitheats spantancoust. and no Weatmont fs required. In exome cases,\nsystemic toatment wih ertromycin Yor up 10 one tri may be\nhelp in cases with achovent or fisted impact canage\n‘ay be caried out and anbtuborsous drugs inated Heal, although\n‘Syslome art ubercuous drags ave notlactive.\n\n22. Severo Adverse Events\n‘Systemic infecton by BCG Is 2 recognized but rare consaquance of\n‘raconation. an oly soon m chisron wh sovare mena defenses\n“uch as Severe Combaned immune Defesency, Chrone Granulomatous\nSiseaso oF D1 George syndrome. Other rare adverso evans chee\n[BCC ostetis and esteomyets (WHO, 1998; 1999, 2000, vel 1)",
            "extraction_method": "ocr"
        },
        {
            "page_number": 12,
            "text": "3. VACCINE EFFICACY\n\n[BCS vaccine has high protective affleacy (approximately 90%) aginst\n‘moringoal and ilar tuberculosis in esto. Homver tho protecive\nCticacy agains! pulmonary asoase ls varlabl, ranging ram O% 0 80%,\n‘wha lower dope of rtachon i topical egiors(mencan Academy\n‘ot Pedals, 2000; WHO, 1999, lve).\n\n4. STORAGE AND ADMINISTRATION\n\nBOG vaccine should be stored and wansported at 2C 10 &°C. The\n‘dives should not be frozon but Kopt coo. The vaccine must be Kept\nfotrgerae. and once the civent hae been added sed win 4 Nou,\nland opt away tom ight (Academy ef Mocicine of Malaysia, 2001.\n‘Adminstration of BCS vaccine is tough ira-demal wjeton with 3\n25.026 gauge need atthe dtd ropion ofthe upper ar, which wil\nIinmize post vaconation lymphadenopathy. Other less satsaciry\nTachagues ute porewanecus iyacions and Use of ft Injectors OF\n‘ifreated needs,\n\n5, IMMUNISATION SCHEDULE\n\n[BCG is cureny recommended at bith, of at fst contact wit neath\nServices. Tore ste scent evidence on the affeay of booster\n‘otos for BEG WHO, 1088, 1098 love!) (Grade A\n\n6. SPECIAL SITUATIONS\n\n6.4 Premature and Low Bith Weight Babies\nInfants less than 33 weeks at less aly to develop BCG scar and a\n‘oacivo PPD luborcu test aor BCG vacsnaton Prmalire Dabo\nthus need not be given BCG vaccine unl ay ae a loaet 34 woeks,\nand wih body weight more than 4800 to 2000 ¢ (Sedaghatan etl,\n5098, fove! 0) (Grade C\n\n162 _Bablos born to HV positive mothers\nBBC should not be admelerd to chlren wih symptomatic HIV\ninfecton. However, for babies bom fo HIV positve motor, since the\nHIV status earmot bo dolermined al bth, es none are Ikely to have\n‘Symetoms of HIV infecion, WHO recommends that they be\n‘dmanisteed BCG. vaccine, especialy Ih afoas where the ak of\nTuberulss i igh (WHO, 1998; 1000, evel 7) [Grade A]",
            "extraction_method": "ocr"
        },
        {
            "page_number": 13,
            "text": "DIPHTHERIA, TETANUS AND PERTUSSIS\nrRODUCTION\n\n1. Diphtheria\nDotnet an ni intectiousdasase aflactng tho upper respieaory\n‘act and occasionally skin, vagna nd conjunciva, The cles!\ntmarifestations result tem ho acton ot an exotoxin rodiced Dy\nConmnebacteum dihtharie, Diphtheria is acquired tough personal\n‘contac. the incubation peiod being genaaly 2 40 5 days. Iie a\nToile disease in Malaysia. Thee sa amanshing wend in Inconce\nfom 0.11 por 10,000 papuason in 1088 to 0.02 9 1008 (Minsey of\nNeath Malaysia, 2002, eel 1)\n\nDoha toxoid i, produces by groweg C; diphtheria ino auld\n‘edluim Ineating the trate ath orale to conver the toa 10\ntorois, which is free purbad. and concentrated To achieve. the\nIecossary dosage. tual absorbed on to an adjuvant hor\nluminum phosphate or uminum ‘Rydroxde. to incense. the\n[emunogonity (nstry of Health tayo, 2002, ove 1: Academy’ ot\n‘Medicine of Malays, 200, ove).\n\n12 Tetanus\nTetanus is an acuto disease caused ty a highly potant neuretoxn\n(etanospasmin) produced by Closrism tetany, wich acts athe\n‘myoneualjnction of shaotal musce, an on neuronal membranes\n{he spinal cod, Bockng inttry Impuses fo motor neurons. The\n‘Ssoase is characterised by mucllr #gidty wh. Sypecimposed\n‘gonising contactors. Th Docitas grows anaerobically of to sto of\n‘wounds Tetanus spores are preset inthe ol and may be invosuced\niio the body ducing Inury trough puncte wounds, bums oF tial\nvwounds. Ir not spread from person to porsn, and the Incubation\nPrsiod may vary fom 2 days to 2 months, averaging about 10 days\nSithough most cases oocur win 1¢ days. Shorter incubation peiods\nfe said be assocated wih more heavily contaminated wounds, more\nSovare disease and a worse pogneats Death results Hom fospenary\n{are hypotension, or cardiaearhytmias (Misty of Heath Malaya.\n2002,\" vol {American Aeaomy ot Pediat, 2000, leva!\nDepartment of Heath, Utd Kingdom, 196, lve! Natlenal Heath &\nMagical Resoarch Counc, Australi 1997, ve 1)\n\nTetanus is» notfabto ésoase 9 Metysia, wih the reported incidence\nshowing a gonoral dimahing Wand Worn 0.08 por 100 000 popuation\nin 1988 to 0.06 1998 Minch of Heath Mays, 1900).",
            "extraction_method": "ocr"
        },
        {
            "page_number": 14,
            "text": "Tetanus vaccine toxoid extracted fromthe toxin rough cute of ©\nlelanc Tho col eo product's. daloxed ater Woatmont wih\nformaldehyde. and usualy adsorbed on 19 an avant (citer\n‘lumii phosphate “or” alumoiim hyeordde) wo Ieteaso\nIEnmunogensay (Misty of Helin Malaysia, 2002, vel 1: Acadamy of\n‘Movdeno f Malaysia, 2001, ove! 8).\n\n1.3. Pertussis\nPanussis or whooping cough’ Is highly contagious disease caused by\nBordo ‘an anrobic. gran-negalve coccabacius. that\nInvades the epilum of to nso-pharynx, bron and brochiles\nHuman tanemission though across ope. The asymptomatic\nincuboton ptod ie 7 1 10 days (ranging tr 6 to 20 aye), flowed\nby the calartal stag of 2107 days, and nly the porxyamal cough\ntae, 8 wks, Al henna cough some cn aa\n\navalable since t may be underreported (Minty of Healt Malaysia,\n2002, lve! 1).\n\nSystem\n{hs vaccine resulod in a-dop in vacsnalon upiaka and subsequent\nFesugnce ofthe disease in many counties nthe 1980's and 1900,\nConsequently. many developed counties aro curently using the\n‘cobalt ports vaccine nthe inmusnsation programe\n\n1.4 DTP Vaccine\n\nCombinaton vaccines of dhther,telanus, and pertussis toxoids are\n‘of two types - whole call (OTP) and cota vaccine (DTaP), OTP is the\n\n(of Heath Malaysia HTA, 2002, ove",
            "extraction_method": "ocr"
        },
        {
            "page_number": 15,
            "text": "2. ADVERSE EFFECTS OF VACCINES\n\n‘hore has boon mach pale once on he adverse reactions to whole\ncapers DTP vacznes, primal Tocuted on the whole co\nDtusis component of the vaecine. The side effects Include led\nStem, and anaphylans reactions. The frequent local reetions are\n‘rythm and indaraion wih or wahout tendemess (Cody, 190%, ve!\n‘9°A nodule may occasionally be presenta he njocton se for saver\n‘wooks, whe stile abscostes hve been por 10 occur 6 10 10\n‘ies per one milion doses of DTP (MMWR, 1991, love 1)\n\n21 Systemic Reactions\nAla syateme reactone ko fover, drowsiness, fretness, anarxia\noccurs raquently (Cody 1981 ive! 2). Fever usualy occurs 24 hours ot\nlater atr vacinaton. However, if ho over persists for moro than 24\nouts. should not bo assumed oe due to DTP vacinaon (MMWR,\n1991, eve: MMWR, 1996; Tove! 1.\n\nModorate-lsevere systemic evens occur nequenty and appear 10\nbe wot sequelae. These include high fevar (a omperature roar\nthan 40.5 °C), wihin 48 hours, unexplained by another cause\npsisent inconedable crying fasing for 3 hours or more, win 4\nFours of immunisaton; conapse or shocktke epsodes (hypotonic\nIrporesponsio opodo) win 48 urs occuring in asa to 1.780\noeos adminstored (Cody, 190%, lov #. or aertived convasions\n(sual febrie) occuring within 3 days (Mirsiy of Healt Malaysia,\n2002, ve: Amercan Academy of Pokaice, 2000, vel?)\n\n‘There is consistent evidence of camlaion betwen OTP vaccine and\nscute encephalopaty. although i has Seon fsulicnt lo estabesh\n‘ausaly (Bara, 1888, ovr &: Mier, 193, lve 8; Cowan. 1993 evel\n‘5, Sima. casal olatonsnip betwoo OTP vac and parmanent\neurologieal damage has nol boon established (Cowan, 1989, ove 1)\n\n‘oporbng f CDC i 1078 (MMWR, 199, vel 7),\n\n‘Severe reacsons to vaccines containing diphtheria or wlanas anigans\n(OT) ae oxrmaly rare. An immediate anophyfacc reaction o tetas\n42nd dohihera toroid conlaning vaccine (e DTaP. OY cr DT) is 2\nontandcaton to farther doses unos the pant can be dosonsiiced\n{a these tnads, due to uncertainty a 1 which vacene component\n(phir, portisis or tetanus) may be fesponsiio, Persone ho\n‘erperarce naphvacicregctons may be teered to an along for",
            "extraction_method": "ocr"
        },
        {
            "page_number": 16,
            "text": "‘evavaton and poastte dosorsitzaion (Ministry of Health Malaysia,\n2002 lve! Amancan Acadomy of Pesaes, 2000, ve! 1)\n\n‘overuse of tetanus toxold can resut in polyneuropathy with an\nstates eldence of 0.& par min doses of eta toxoid (Minsky\n‘St Meath Malaysia, 2002, oe! 1.\n\nDespite some case reports, no increased risk of Culiain Bare\n‘Syndrome has boon cbsorved wih the use of Llanos toxoid in whale\nstile ead pertssavoenes Nato Healt) & Meal Research\nCounch, Astral. 1087, fool 1) once, no spocal precautons\nfooted von exnunaing charen wir a hakoy of Sultan Bare\n‘Synarome (istry of oak Mays, 2002 vel\n\n3. VACCINE EFFICACY\n\n3.4. Diphtheria Vaccine\n‘The most important factor of an ago host response to immu wh\nSphiheia toxoid isthe moving flock of postvely acqured matorral\n‘abodes in young intants. This passive dpiera anibodies se0m to\n‘how a rarsiont antibody response suppression tothe second injection\n‘NDT vaccine, aihough, Bre hae beon ro response To the thet\nInjecton of DPT vaccine Misr f Heath Malaysia 2002 vel).\n\nPrimary immunisation with 3 doses of OTP vaccine stiulsts the\n‘roduction of iphthera. antbody Tove in considerable excess of the\nIrina protective lve (001 Win). However, wha tral erry\n‘Se long, the duration of mmunty aor a prnarynmunisation sora\n‘@ vaable. \"Stsios on tis fae havo sowed iorng ross, wth\n‘duration of immunly ranging om 3-10 years. Tis could be due to\n“force in vaccines, vacanatonschedles and aves of commu\nfxposure lo Corynebacterium dphherie presence of nalural boosting)\nIn contrast, a booster dose at 2 years or at school etry (48 yaar)\nSlates abundant reduction of Sphownaanitonn wit mean Wve\n‘ove 0.1 WU. There is no defined love! of anion but ls blloved\n{hat 0.07 Win dose of Oiphara a enough for clrscal immunity\nagainst the dsease, while 2 dose of 0.1 U/ml may be needed for\n‘rotecton Mins of Heath Malaysia, 2002, ve! 7).\n\n“The oflectvoness of 3 or more doses ranged ro 87 to 99.9% (Biogard\n‘t's. 2000, lve! 9; Chom otal, 2000, love! 9) Schooicren who\n‘ectved booster doses expaienced protecton against respiratory\n“phnela (Bogard ta, 2000, ove! 8) In Rusia, was is found\nthat boosie doaos gen at 68 years provided improved grotecton\n(Vitek tat, 1999, ove 7). Thus, tis recommended that Ophir Bo",
            "extraction_method": "ocr"
        },
        {
            "page_number": 17,
            "text": "von 253 primary doses wth a boasar a year arth primary doses,\n{8 wol a anohor at 6-8 your of ge.\n\n32 Tetanus Toxoids Vaccine\nTetanus owes has an eflcey of move han 95%. Elective protection is\n[rovded by active immunisation, with complete primary immanisaton (3\novos) config potecon fra east 5 you's. many wa lato\nleast 10 years aller the 4” dose, and 20 years ater the 5” dose\n(Misty of Heath Malaysia, 2002, eet 1.\n\nA totanus anitoxn love of 001 in! serum is considered 38 tho\nmisimum protective level (Chon, 1976, vel 1} Caso reports have\nShown thal for patents wah aationnlavet mora than 001 Wa the\nSavoy ottawa vert proportional othe aston vel,\n\n23 Pertussis Vaccine\nThe efecivoness of 2,3-dose whle-cal perussis vaccination was\nbetween 71 to 90% depending on the case defeaton usd (00 Serres,\n1296, love! 6) Aceblat OTP wth mare than thee component peruse\nvactnes was foun o be loss offeacous than Bose with 203 whol\n‘vaccines Tieion, 2000, vel 1) Mest sludes mansure peruse\nBntionn (FHA anitodies) and loves above 0.01 Ula! are concord\nto be a rosponee fo the acco, affording & minimum protacivelovel\n(iisty of Heath Malaysia, 2002, eet 1.\n\n4. STORAGE , DOSAGE AND ADMINISTRATION.\n\n4.1. iphtnria Vaccine\nDiphnea vaccines shoud be stored at 2 °C to 8 °C. the vaccine had\nbean zon shoud net bo 400d (ney of Hah Malaya, 2002\nlevel Academy. of Medicine of Malaysia, 2001, Jove! 9} The\n‘ocomaonded dose |e 05 ml given iamunculey (Maia of Malays,\n£2002, ovo 1) (Grade A\n\n42. Tolanus Toxold\n“elanus toxoid Is slable and able to withstand room temperature for\ntorte (WHO, 1095 fove 1). However, tans vaccno if port of OPT\n‘shouldbe stored at 2-8 °C, and shows not bo tazen exposed to ight\n{Wins of Hatt Malaysia, 2002, toe! Natonal Noah & Medel\nResearch Councl, Auctaa, 1997. love! 4; Department of Health\nUnitod Kingdom,” 1998, evo! 1). The. doo” ie D'S mt gwen\nIntramasculty Fr primary lneunieaton olaus vaccines shoud ot\nbe given as 2 moracomoanent vacsne, bt combined wth iphhena\n(01) andor pertussis (OPT) (nity of Health Malaysia, 2002, love 7\nNatonal Hoaih & Motkcal Research Covned, Asta 1297, level)\n{Grade a)",
            "extraction_method": "ocr"
        },
        {
            "page_number": 18,
            "text": "43. Pertussis Vaccine\nPerussis vaccines should be stored at 28 °C and should not bo fazen\n(Qtinsuy of Heath Malaysia, 2002 ove! 1; National Health & Modal\nReseareh Counc, Austra, 1997, love! 1. Deparment of Heath\nUnited Kingdom, 1996. eve! 1}. The dose’ is 05 ml gen\n‘namuscutary ai 9 90'engo toto skin, Tho recommended ate of\ninjecon & the antrlatera aspect of tho Wigh fr infants, wile for\ntoddlers upto 4 years of age, the dello muscle i te recommended\nsite (ACIP 2002) [rade Al\n\n5 ACCELERATED OTP IMMUNISATION SCHEDULE\n\n‘The fst dove of OTP at 3 month of age has bean said obo o0 lle to\n‘fold infants against pertussis (National Heath & Medial Research\n‘Counet Atala, 1097, love! 1; Bart, 1000, jot 1). thas boon shown\nthat te fst doso of OTP can be lowered to 8 wooks of age witout\n\n‘comeromising imunogeniciy, Tor both te wholo coll and. scolar\nDertussle OTP vaccines (WHO. 1005, fv; art, 1900, tovel 1,\nRamsay, 1993, vel 9: Eanards, 1005, ove! f: Gustafsson, 1096, fvel\n1). Booster doses of OTP al 12-24 monihs and at 46 yours ae\n\novo) ) rade Ay",
            "extraction_method": "ocr"
        },
        {
            "page_number": 19,
            "text": "POLIOVIRUS VACCINE\n41 IntRopucTION\n\nPomel is an acate val infection ranging in savory rom a non:\nspect ness fo paras with parmanent aaby. About 90.5% of\nbows infecion is asymptomatic, wo non: speci ness wth ow\n{Grado Tover and sore teat occurs in 48% cl inectons. Asopte\nmening with parastwsia occurs in 15% of patents ow says ater\nthe minor tnoss has resolved. Rapid onset of async nc Nacid\nparalysis with artiona ety lbs occurs in 0. 2% of etectons,\nand residual paralyie disease imaving the motor nowrons (paras\n‘oomyeits) occurs in approximately tm 250 lfectons. Cra nore\nInvclvement and paras of Tespratory muses may also occu,\nFindings of mid pleceyioss and mphocye edornance in tho\n‘cerebrospinal ad {CSF} are charactors of wal moningis,\n\n‘Akits who contracted paraite pollo in chided may develop\n‘te post goo syndrome 30-40 years late, characteeed by mince\n‘iin, oxacorbaton of woukness, andor new parva or weakness\nThis secondary ness resembing motor nouren disease after an\napparent stort paiog is somatmos known as lle post posom volta\n‘muscular atrophy. Rsk facrs that may atc ho potential for maton\n‘wih pollowtus or the soverty of cnicl posomyets Ince mon\nefilency. injections, maiilen, piysien achvty, pregnancy and\ntonelactomy\n\nFour types of poovinas vaccines are curenty aiabie - inactivated\npolo vaccino PV) of Sak, oral poo vaccine (OPV) ‘of Sabin,\n\nInactvatod vaccine of Van Wess (PV) and\ncombinations wih or vaccines the DTPSPV. Tho vaccines aro\nttvalent containing a mitra of he’ Sane of pokowus\n\n2 ADVERSE EFFECTS\n\nhore havo been many report of Vaccine Associated Parayte\nPotomyeits (VAPP) due \"> OPV, wth an opedomlogical stay\n‘estimating the tk fo bo 13 cates por milion vaccines. PV soos nt\n‘cause VAPP and Is curenty recommended Yo srovent VAPP in 8\nSequential regime. Howover, oer studies have reported. adverse\n‘vents det PV ike toca eacion a iyocton se (43%) neucloge\ndisorders (12%). hyportenson (10%) ana alergis reactone (10%)\n‘Other rare out sevous sido effets Iko prnistnt eying, abi seizure,\n‘apyete seizures, uneasiness and shock have been reported (Min\n‘of Meath Malay, 2002, lev! 1).",
            "extraction_method": "ocr"
        },
        {
            "page_number": 20,
            "text": "23, VACCINE EFFICACY\n\n‘Thor ie good evionce that OPV is efeacous.Chisron with darthoea\nreoching OPV should be resmmunised once the agase has resolved\n‘Since thas boon found that sarthona Isa major factor in vaccine fare.\n‘Th seroconversion rate forall ypes of pokovis was found to be\nhigher fan extra doso was gen at bit) if counties where\nDotiomyalt sa problem” OPV ale found afectve when givan ©\nDole babies at 34-5 weeks of gestation (Ministry of Heath Malaysia,\n12002, fave!\n\n{V was found 10 be as eficacous a= OPV. It was also found that\n‘troresponsas 10 IPV wore excatan! and uaffeced whan combined\n‘as obwr vaccines Into same singe. Howover. oe study found that\nthe immune response to persis wae affected by combing OTP ond\nIPV Qnty of Heath Malaysia, 2002, ve 1)\n\nVaccines combicng IPV vith OTP ore avalable. In adkitlon.IPV or\n(OPV can bo gen concurenty wih many oher yacones te OTP,\nHepaits BH, moasis or aR and Vario\n\n4, STORAGE, DOSAGE ANO ROUTE OF ADMINISTRATION\n\n‘The cold chain of polo vaccine shouldbe maintained, and both OPY\nand IPV vaccines shoud be sored Inthe rokigerator at #-10°C. OPV\nshould be stored bolow 0°C Afr thawing, i may be stored between 2.\n{8°C.IPV should ba stored at 28°C.\n\n‘The route of odministaton of OPV is by orl ops. wile IPV Is\nIntramuscaar, on, Be anterolteral aspect ot the thigh oF am oF\nsbeutaneoushy. Totracog (OPT APY) is adminstoreditamusculary 28\nDTP vaccne isan agavant\n\n'5. IMMUNISATION SCHEDULE\n\n‘Wo recommends tat 4 doses of OPV be gion by 14 wocks of og0,\n‘witha doce at bt in counts whore polompalits i sua prior. A\nZier sorval Io. doable between the fret 2 doses to avd\ninteerenco wit repicaton, “the. minimum nfenal ia most\n‘roumatancos being 6 wooks, The 3 dose recommended whon Do\nchi Is 6-18 monthe to completo the prmary soles, and a\nSupplementary dove gvon bore entong school ie. at 4-6 years of\n‘go For con not mmunsod i to Wt yoar of fo, 2 doges of OPV\nShould be given approsinately 6-8 waoks spar, flowed by thd\n‘doco 2-12 months intr. [Grade Al",
            "extraction_method": "ocr"
        },
        {
            "page_number": 21,
            "text": "Fer chideon immunised with IPV ony. the eimary series consists of 3\ndoses, The fest 2 doses shou be’ given at 12 month (&-8 weeks)\nIntnvais Dogining at 2 months of ago (mawmum ago 8 wooks) and 3\n4 dose Ta recommonded 6-12 months aftr the sacond dose. A\n‘supplemental dose of IPV should be gen before the chld enters\nSchool fe 4-8 yours of 090. (Grade Al.\n\n6 SPECIAL SITUATIONS,\n\nIPY is recommendad in special cases tke immune-conpromised\nDalonts such as Hivanfected and ther Household cortact, since OPV\n‘contanceated (nity of Healy Malaysia, 2002 ove! 1) [Grade A]",
            "extraction_method": "ocr"
        },
        {
            "page_number": 22,
            "text": "HEPATITIS B VACCINE.\n4. INTRODUCTION\n\nHepatitis 8 (HB) isa major chore via ess workuide with longterm\n‘omptcatons of eho and hepatocedlrcarenoma reuling hgh\n‘morally and morbaty.” AS the woatnent i far fom sabsfacory Bo\nbest strategy is prevention. Thoes ince ace snmunsation wth HB\nocane, avoldance of aiisk Behavour and posse. sources of\nTraramission, and st adhorenee to unreal procautons and 900d\nInfection conv procodurs (Nanay of Haat Mays, 2002 ve)\n\nInfants who become infect by perinatal transmission have 980% Fok\n‘ot evoni focton and a 25% rk of eying f vr cancer Fuster,\nthlsren youngor than 5 years of ageing wih a person with hops\n8 iefocin can become ilcted va horizontal tanamssion and 380\nhavea higher kelnoad of chrom infection and subsequent cons ot\nCancer in erly adltood. In Malaysia, te eidence of Khas Jocinad\n‘tom 9:38 per 100 000 populaton in. 1988 to 297 per” 100.000\nPopulation ip 1996, However, there are sll about milo hepatitis B\n‘armor inthis county or about 5% of to populaon (My of Heath\nMalaysia 2002, ove).\n\nHB immanisaion provides adequate protection in the. msjotiy of\nrecplonts and provera both versal and Borzorlal Wanamsaion. TNO\nhepatts 8 vacane contains inacvaled RepasB wus surface antigen\n(HbsAg) adsorbed eto aluminium hydroxide adjuvant. Sovera highly\nfecve and sale hepalitsB vaccines produced by recombinant DNA\n{echnology are avatable. The original plasma-derived vaccne is no\nlonger recommended (Minty of Hoa Malaysia, 2002. vel)\n\n2 ADVERSE EFFECTS\n\nHepatits 8 vaccine is genoa safe and wll floated. Tho most\n‘common adverse reactions ara ransient soreness and redness. at\ninjection ste, lw grade tomperstre, nausea, dzness, male, rsh,\n‘an iiuonzatha syndrome, onus, arthaiga and myeig, thal occur\nToss troquety in infants and crudren than adults. Those sympioms\nresoive whi 24-48 pours of vaccine administration, and te Weduentcy\nOf ese reacions decease win subsequent doses of the vacae,\n‘Merte ractons have been repetod infequeny nd anaphyls\n‘ory rar Wins of Heats layla, 2002 vel 7).\n\nCases of GuliainBare symtoms, rheumateld atts, emyetinating\nCseases of the central neous system, and Iehonoid reaction have\nboon opted afer hepaths B emmuniaaton. However, thre Is 00",
            "extraction_method": "ocr"
        },
        {
            "page_number": 23,
            "text": "feidence of an association Between vaccination and sudden infant\nSoath syndrome, mitiplo scrosn. aaunmuno doaee oF GwOr:\nfigue symarome [DeBiase ot al, 2002; Amotcan Acadamy of\nPedhatis, 2000, evel 1\n\n‘Thimerosal isa derivative of ely mercury and has been used\nfroseratve in vaccines since the 1980s for fs ofleacy hn prventng\n‘acter contamination i opened, mul-cose containers. Theres mo\nonvining evdencn of tnt frm doses of Tamorosal sod\n‘acdies (MEPhps & Marcuse, 2001, eve 2)\n\nVACCINE EFFICACY\n\nHigh sorocanvorsion rates and protective concentrations of ant-Hbs\n{2tOmivim) are achieved when hepatis B vaccine s administered\nSry of ho various dose schodulos, indudig those bogun boon ater\nrth in term nan. The use ofa 3-se regimen has bean shows 1 be\ngil effeacous. The vaccine is eflctiven roveniing HB nfcon\nChdwauals who produce pectic ants Hbs (hissy of Hoss Maiayets,\n2002, evel). The immune resporse using 1 oF 2 doses ofa vaccine\n‘produced by one manutactwrerfolowed by 1 of 2 move subsequent\nSoses from a diferent menfactuer had been demonstrated obo\n‘omporablo 1 a kil couse of maraaton wath a single product For\n{hlafen wth normal immune slats, rouine Booster doses of vaccine\n‘10 nat commended (Amarican Academy of Pediat, 2000, val 1).\n\n4. STORAGE, DOSAGE AND ADMINISTRATION\n\n‘The vaccine shoud be stored at 2 10.8 °C. Froozing wal destoy is\npotency. The vaccine is wo, stghity opalescent quid, Any vile\nhangs in Be product such as prociptates, may incate Peorret\nStorage condtons and consequent reducton in immunogency. Such\novones ‘spould be discarded. The dose of vaccino is 05 ak,\n‘smietstord rasta in the antoro-aeal igh fr neonates ed\n‘ants, and We dotld area fox chaaren.Admbtvaten invader\n‘tho buttocks has rosstod in poor mane response, and fs hus nt\n‘recommended, Saiancous admnsiaton wi thor vaccibes at\n‘Sifoent ses ie sto and eficalous (Misty of Heath Malaysia, 2002,\nlevel 1, DeBiasa et al, 2002. level 1) In pation with a Bodin\nathesis, the rik of Bleeding ater intramuscular vaccine infection can\n‘be mvmized by admintraton irmodataly ator the patent receives\n‘placomert factor, uso of 2 23-gauge  rawdle of malt, and\nSoplcton of roc presauo to the tmmuration ak for al last 2\n‘mules (Arorican Acadamy of Pedi, 2000, fovel 1) {Grade A)",
            "extraction_method": "ocr"
        },
        {
            "page_number": 24,
            "text": "5, SPECIAL SITUATIONS\n\n5.4. Infants Born to HbsAg-Postve Mothers\nInfants bem to HDsAg-poatve meshors shouldbe claansad of blood in\nthe delvey room. Both hepats 8 vaccne and HBIG (05m\nInramascatary) shoud be given simstancounly at aeront silos a8\n‘oon as possible, prefrabiy win 12 hous afer bith. Subsequent\n‘doses of Popatis B vaccine shall be gon as fecommondod\n\n5.2. Preterm infants\nFor prot ifnts wo weigh lass than 2 kg a bit he ni vacing\ndose shoud not be counted in the required 3-dose schedule. Thus. a\ntotal of coaoe are recommended in bis secumstance, These infants\nShould be losted serlogealy Yor antsHBs and Haag 1 19 3 mons\n‘fer compton of tho munsaton series. Infants with ant Hs\nConcentrabone of less than TOmiUiml and who are HOsAg gave\nShould reenve 3 acatonal doves of vaccine at 0, 1 and 6 mons\nTotowed by testing for antMBS 1 month ater to ted dose (DeBiava ot\nal 2002, American Academy of Pediat, 2000, level 1.) {Grade A)\n\n5.3. Serologic Testing\n\n‘Suisapitaty tsting efor immunisation i no ndcated routinely for\nchron or adolascons, Roun post-inmunisaton testing for an-HBS\n‘is alco net nocessary. Howovor, tasting i adised 1102 months afer\ntho third vaccine dove for patios on hemodialys, persons wi) HIV\nInfocton, nose a occupational risk of exposure fom sharps injsies,\nImmunacompremised patents at risk of exposure. to HBV. rogdar\nSonal contacts of HbsAg-postve persons, and infants bor to HOSA\nostive motors (American Academy of Pants, 2000, love 1 )\n{Grade A}",
            "extraction_method": "ocr"
        },
        {
            "page_number": 25,
            "text": "WAEMOPHILUS INFLUENZAE VACCINE\n4. INTRODUCTION\n\n‘Haomophlus intuenzae is a respiratory pathogen of humans causing\n{nfoctors ranging tom asymptomatlealonzation of tho. upper\nrespirator tract lo serous invasive dsease is an important patiogen\nin-ehren causing consterabe morbidity, morally and bwalth care\nfxpense, both workwide and locally (Minit of Mealh Malaysia, 2002,\ntowel\n\nlieasive disease is associated with encapsulated strains of the\n‘organism. There ar sx capsular sortypae dvignaled of, he may\nOf invasive dasases being causod by Hoomophius Inivenza0 type 8\n‘MeningitsIs o most common invatve Hemogius iatuonza type B\n{WH0) ntecton” Most cases of He meninglts in Malaysia cea nt\n‘hacken onder 12 montis 0. and ils rarely encountred in ose\nLindr'3 montis and beyond yrs of age (Misr of Heal Malays,\n2002, ove 7)\n\nTho Hi vaccines avatable presently consist of polbosyibito!\n‘hosphato (PRP) chemically inked (conugatod) to a vary of car\nbros Th care tenes» goed andy respons he\nip capsular polysaccharide, Four types of vaccine ae. svallabie —\n[PRP-ouer mambrane prooin conjugate vaccine (PRP-OMP), PRP.\ntetanus taxed connate (PRP), PRP-Hib oligosaccharide conjugated\n‘cane (PRP-HLOC) and PRP-phtwia tox. conjugate. vaccine\n(PRP-D- of hich only the fest are caeily avaiable in Malaysla\n(ity of Health Malaysia, 2002, ove! 1),\n\n2. ADVERSE EFFECTS\n\n[Adverse reacions to Hi conjugate vaccines are few. mostly pain,\nfednass, ond aweing al Inecion sto, occuring In about 525% 0\nfecblons. \"These symptoms ae mid nd as for oes than 24 Fours.\n‘Sytem roactons such as tover and rab aro requont(Menity\nof Heath Malaysia, 2002, eve).\n\n‘The combination vacine (OTwP +H) Is wll lrated by infants and\nfo sigaiicart sidefocs havo been reported (Mristy of Health\n[atayia, 2002, lovel 1: Hussey, 2002, Cheon, 2002: Are, 2000).\n‘Tho Toca reactions reported were mainy. ansiet pain. reds,\nInduaion and somo low grado fover (Loko. 2001). No vaccine:\nTalated serous adverso ewonts have occured when (OTaP-PV) and\nHH vaca aro od, efthar whan moxod i the samo Syringe or givan\n‘Seporaty (Keutsson, 2001). blower incience of adverse events has",
            "extraction_method": "ocr"
        },
        {
            "page_number": 26,
            "text": "ono martin\n\n‘been reported folowing he HbDTaP combination vaccine compared\n10 he Mabe T WP (Gyea, 2000, evel 8\n\n3. VACCINE EFFICACY\n\nThe protctvo euporonty of any one othe thrve vaccine « PRP-T,\nPRP'OMP and HBOC ” has not been demonstrated, and ffca°y\n‘sues inate that those vaccines are sutale Tor prevention of\n‘Saoace in infants and chien In fondomzed “comoled tas,\n‘antibody response to sme vaccines was higher alr th st doo, but\ntho levels wore nol sgnticanty diferent ater 3 doses (Mnsty of\nHealth Matasia, 2002, level)\n\n4. COMBINATION OF VACCINES\n\nEffective immunisation of chien against multe dseaso best\n{ackled by giving several ansgans in one injocon. The preparation of\nthe ge nection coud be done afr Sung manulactwe of vaceines\n‘or immediately betoreadmistvatn (Misty af Health Malaysia, 2002\nvert), DTW? mixed wth PRT and given concurreaty with OPV,\nPRP-T mid wits OTwe, DTPwIPV mixed wah Hib and separate HEV\n‘achieved satstactory anibody preducton against PRP (Araujo, 2000;\ninst of Hoan Malaysia, 2002, lool 1. Thar was no interference to\n‘ny ofthe components when OPV, OTOP and Hib vaccine wore given\nSeparately or won DTaP ray mixed wilh Wb and gen wal OPV\n(Ronnels a, 2000, vel 2).\n\n‘5. STORAGE, DOSAGE AND ROUTE OF ADMINISTRATION\n\nConjugate vacins shouldbe slr at 28°C, and mus ot be frozen,\nEach dove of congugat vaccine f 0.5m and giv armen. Tho\ntie of taesonal dove regimens showed adequate serlogeal response\n\nSand mmunologeal memory (Ministry of Heats Malaysia, 2002. eve\nFerrandez 2000) (Grade A)\n\n6 scweDULE\n\n‘Thee is good evdonce that immunisation wih dee doses of PRP-T\n‘ncene at2, 3,4 0F2 4,6 mons fs igh sumanogenc (Minis of\nNosh Malays, 2002 ove 1) [Grade A)\n\n“The high elicacy of PRP-T oven in infancy and vetual Seappearance\nof th dso inthe UK, suggest thatthe booster dove may nol Be\nFequred fo a popuaton here high vaccination coverage (°90%)\nSachieved (nist of Hoalt Malaysia 2002; love! 1: Heath, 2002),\n{Grade Al",
            "extraction_method": "ocr"
        },
        {
            "page_number": 27,
            "text": "A single Hi vocdne dose is efficaclous in peoventing Hib invasive\n‘disease incon between the ages of 1-4 year. The nee for catch-\nSp shoud always be conidored when vodkeng Mb vac in routine\n‘rmunsation programs (Gal, 2002) (Grade Al\n\n7. SPECIAL SITUATIONS:\n\n7.4 Promature Babies\nAough most imal infos may show an inadequate\n‘response {othe fl rmunisation, mary oto nants bat om\n‘ccnaton hen Immunisation is\" \"commenced at the. same\nrondogica \"age as tom infants (Krstonsen, 1006; -Amwrican\n‘Acadeny of Poatics, 2000, val 1). {Grade Al\n\n7.2. Thalassaomia and Splenectomy\n\nib conjugate vaccine fs immunogenic a patents wth Thalassomia\n‘major srespective af whether or nota splenoetmy had Boon porto.\nHowever. the ead as well asthe tmeg of Soostr vaccinaton 10\n‘maintain tng-arm immunity hos 10 be assessed (Cimaz, 2001 ev 9:\nKtstensen, 1904, level & rosin, 1992, ove 8). (Grade C)\n\n73 HIV Infection\nThe eflectvenoes ofthe Hb conjunated vaccine has bown found fo be\nreduced in HIV infected tors (Read, 1898, evel 8; Gib, 1985, 1096,\n‘evel & Rutsen, 189, fvel& Poles, 1896, eel 9, Madhi, 2002 ove!\n{Thay wore found to have Were beiow tho protcivn love at 1 year,\nfd thm, tho need for ronson of chase with HIV ‘nection\n‘gaint Hib requires tutor ovluaton (Gb, 196, lve! 8). (Grade C)",
            "extraction_method": "ocr"
        },
        {
            "page_number": 28,
            "text": "MEASLES, MUMPS AND RUBELLA VACCINE\n4. INTRODUCTION\n\n44 Measles\nNason ta bighy infectious veal (RNA) soase anda major host\n‘ssuo. It afects almost tho entre population in the sbsence of an\nlmmenieaton programme. Measles is wansmitled  vimarly. by\n‘ospratery drops fm person to person. Prmary wraemia occurs 2-4\n‘dye folowing exposure win an intones socondary veer occuring\nSHY aye later Communty “stutos in dovloping counties, have\nocumorted case fatasy rats of up to 15%. The mortally s highest\nIneadren under 2 years of ago, Bote who are malnourished, and hang\nin cowed conctions (Minty of Heady Malays, 2002, evel 1)\n\nMeasiog vaccine 1 a lve atanuatd vaccine cult in chick emByo\n‘ols. The woodne contains a sabisor at rakes f more heat resistant,\nHowever, after reconstiuion, at 22 °C o 25 & wil ose 50% of ts\npoteny, while Bacomes ‘completly ‘nactvatod m1 nour at\ntemperatures of over 37°C\n\n‘The atcacy of moans vaccine Is 5% for persons vaccinated at 12\nmona, and 92% for those vacates at 15 months of ago. A Teal\n‘vation of vacelne offeacy showed seroconversion rates ranging\nftom 93.7-98.9% for chidven god 8:24 month, mi alos bong bet\n{or those aged 11-28 mont (064-98 9%) than those who were 2-10,\n‘mond ei (08 7-98.34) (Misr of Health Malaysia, 2002, lve 1),\n\n‘Tho majorly of vaccinated induais appear to develop Ho long\nimmunity, but wating voce Induces immunity doos ext (sacondary\n\\ocrino fire) Howaver, the. moesios. that occurs. n immunised\npersons Pa boon epodod to ba mir than in hose who woe Hol\nImmunised. Tero is 2 minimum pieary vacine fare rate of 25%\nthen coud be higher the voedne were givon Bofors 12 manths of\n‘ge Misty of Heath Maya, 2002 ve! 7),\n\n12 Mumps\n‘enp i a paramysovrs infection. occurs primary in chien, with\n‘a peak ncdonco it $8 yours of age Camplcaons include pancreas,\n‘ophoit,orets(unateral orchis has been reported in up to 2%\npostpuberal males with cleleal manps, allhough stanly Is ra),\nhepatitis, myocardis and yews. Benign meningeal signe appear n\nUpto 18% of eases, but pormanont eequninn rar, A stows are\n‘Complication is uniateral nerve deaess",
            "extraction_method": "ocr"
        },
        {
            "page_number": 29,
            "text": "‘Mumps vacsine is 9 ive attenuated vaccine prepared in chick embryo\n‘cal Gutures. The most widely Usod strana peoseat Is ert Lyn B\n(Gaksh of al, 1950), while te othr stains avaatle are Rube a\nUrabe. The Urabe stain was witharawn in 1092 ator an aseociaton\n‘wih increased rik of aseptic meningitis was reported in Owe counties\n(Furosz 1990). while the Rub staan has. boon shown 10 be\n‘Sesonated wih pemary vaca faa (Schogel, 1999)\nSeroconversion alr @ single dose of mumps vacone was reported fo\nrange tom 90:100%. Tho uration of vaccine Inced nunty\ntrknown (antbedes have been shown to peril for 9'5 year afer\nMR adminstraion) ba epléemisiogical and serolopeal data ovr the\npast 30 years inscale No perssionce of anibeces and conning\nProtecton against focton tis antepated tha a wo dove MIR pally\nWil eectvty dea with most cases of primary vaccine fale at have\n2 isk of mms in aro (Mitry of Health Malaysia, 2002, fev).\n\n1.3. Rubella\nFuels an RNA vius belonging othe Togailéoe group of ves.\n[is transmitted trough doplel spread, while. cengertal infection\nects as a rosult of vaemia during rognancy. Thetarloganc etfocts\n‘re produced as 2 resut ofan inflammatory response toe Vins and\ndepressed mosis, resulting in hypoplasia in tho cavelping foots\nFubata associated delects occu 100% of pragnancies i inaction\noccurs in tho fst 11 woeks, 50% in infocsons at 1-12 wake 35%\n{15-16 weeks. The cammen pormanoet morestatons of congenial\n‘bola inode sensorineural deatnass, mortal rladaton, extarats,\ncongenital heart detec eUnopaty, spevte dplaga, gow relation,\n‘nepaosplenomepaly,tirombocyopena and meningoencephalic.\n\nFuels vaccine is  feeze-<ded preparation that i stored at 28°\n‘and when reconstuted with iver fi. Is von i dose of 0.5 mi\n‘Subeutaneously. A serum antbody fo rubella ts nducod In atleast 953%\nof recpents folowing 2 singe dose at 12 month of 290 oF lator.\n‘Vaccine inducodanibody as boon shown to porst fora least 16\nyears and protacton agaist cna rubala appears to be Tong term.\nHowever prenary vacono fats. do occur and anabody levels can\nwane (Mise of Hoa, 2002, love! 1).\n\n14 MMR Vaccine\n\nThe MMR vaccine isa freezeciod preparation containing We\n‘ttonuated measles, mumps and ubala vases.",
            "extraction_method": "ocr"
        },
        {
            "page_number": 30,
            "text": "2. ADVERSE EFFECTS OF MMR\n\nThore are minimal adverse reactions folowing vaccination wh MMR\n‘natudng Wal pa, local tration, malaise, fover of a rash that\n‘ously cecurs a week afer inmuntaton, lostag for 2-3 days\nPotential serous complcatons inctude loathe Thronbecyepaenc\nPupusa (TP) (3.3 per 100,000), arhropaty. Keble convasions,\ntena (08 per 10 00) and parotd swing. Howover, the mums\nomponcnt of the MUR vaccine 16 hnown to be associated wih\n‘ments at an estimated rte of 1 in 50,000 fo Tin 1 lion doses,\ntahini for Toss common than with tho natural Hess. (118%)\n‘insur of Heath Mataysia, 2002, ov! 1).\n\nThe current evidence only establishes a causa elation between MMR\n‘ciation and anaphylaxis, twombocytopona, ebro seizures, and\ncute artes. Howover, no causal bak hus boon estate tnking\nTUR fo autsm and fnfammatory Bowel dsoasos (Ministry of Heath\nMalayin, 2002, fvel 1: Madson ata, 2002: Taye ota. 2002) The\n‘oneal cneaincatons to MRR vaccine ae 33 for ave vaccines\n(itinsty of Hoon Malaysia, 2002, Level 1). Athough no anaphylactic\n‘ean associated win’ adminsvaion ‘of MMR vaccine has” been\n‘opoted, tus adverse event can be He eataring. Adrenaline shoud\nbe avalabie for immediate use at any sta whore vaccines oe\n‘admnistored in case symptoms of anaphyans occur (ACIP, 1088;\n‘Amescan Academy of Pocatics, 2000, Pa, 2000)\n\nCitron wh abrgy to e998 can saat receive MMR vaccine since the\n‘are, setts allege feacons afer MNF ae blloved to bo caused not\n‘by eng antigens, bu by oor components of tho vacine (e.g, MMR. RS\ncomponent vaccines, and ober vacines contain hsroyzed gelatin 38\n1 stablzo) (Mins of Heath Malaysia, 2002, ove),\n\n2. VACCINE EFFICACY\n\n‘The vaccine fs Nghtyimmunogenc wih serconversion rales of 96-\n400% for mason, 90:100% for mumps and 09-100% for ribet\nProtecton contered by a sngle dose gien ater 12 months of age\ntong lasing in the majotiy of persons. Howaver between 5-10% of\n‘rccinaled dvduals may eon have primary vaczi fal oF lose\nprotection, while 99% of neds who receive two doses (separated\nBy at eas 4 weeks) aftr 12 mone of ago have long lasting runs\ntomeacls(Minstry of Heat Malai, 2002. ovo?)\n\n‘The config evdance on the offcacy of MM. yccinaton unos\n2 months of 90. Tho hase Down a suggeston tat a mmunisaion\n‘ates improve, maternal anibodies may wane sooner in mothers ho\n{eceived temarsaton rar than the nul dense, hence allowing",
            "extraction_method": "ocr"
        },
        {
            "page_number": 31,
            "text": "Cond maa\n\n{ora lower minimum age for measles and other imwunisation (nity\n‘of Heath Malai, 2002, eet 1.\n\n4. STORAGE, DOSAGE AND ROUTE OF ADMINISTRATION.\n\n|i vaccine should bo store at 2°C to 6°C and must bo protected\nftom ultraviolet hgh. Reconstiuled measles vaccine Is very unstable\nand guy loses potony a room temperature afr reconstuon, ad\nonce shoud be dscardad sat used wi 8 hours even fsore fn 8\n\nrafigerator (ACIP, 1968). The dosage is 0.9 mi given by intramuscular\n\noF degp subeutansous mycin (Department of Heath, United Kingdom,\n1996) [Grade C],\n\n5. SCHEDULE\n\n‘A2-dose MMR is cemented obo gven at 12 months and at schoo!\nfnury (6 to 7 years) However, for Sabah, & is econmenced that\n‘monovalent measles vaccine be gon 1 ehiiren at 6 months of age,\n{lowed by MME at 12 months and at school enky (6 10 7 years)\n(WHO! ACIP 1908). [Grade A}\n\n6. SPECIAL srruaTiONS.\n\n|. Measles Immunisation in HIV Infected Chien:\nHiVntctd chien, adolscants, and yours aduts witout evidence\n‘of severe immuno suppression should receive MMR vacsne. Th fist\ndose should be adminstored at 12 months of age. The second dose\nmay be given as eatly 35 28 days after the fst doue-In th event of an\nCutbeak inthe cormmunty, vaccination wih rmeno-valent moasios\n\\aoane (or MMR) Ie recommended for ifans as young as © mont\n‘wher “exposure to” natural measles is considered thay. Children\n‘agonal before th fst bitday should be revacinated wth MMR. at\n{2 month, and an addons dove may be gen 28 days lle (AAP,\n1900) (Grado A)\n\n52. Steroid Treatment\nPalient who received steroids at a dose equivalent or greater than a\nprednisone dose of2 maka of boty weight pe day. of ttl of 20 mq\nBer day, oF on ater dae for antral of 1 days of longer, shud\n[void vaccnaton wilh MMR and ts component vacsnes for at aast 1\n‘ont afer cessation of slroid therapy Similar, Toso receiving\nDrelonged or exenshe lopea, serosa, of ole cal corlcastorod\n‘hrapy that causes cial er aberatery evidence of systemic emu\nSuppression, should sto ovoid vaccination wi MMR for at lost 1\n‘mont ater essaton of therapy. Such poreons can generaly rocco\nIMMIR. oF #5 component vaccinos, immodataly aor coBtaton of",
            "extraction_method": "ocr"
        },
        {
            "page_number": 32,
            "text": "nine mason\n\ntreatment although somo prefer waiting unt 2 weeks after compton\n(of thrapy. MBIR, or Rs component vaccines, shoud not generally be\n‘admnistred to porsons who have 2 dloeaso at suppresses the\nInmano respons, oF those who ao roclving ether systems ot lca\n‘sdminustored corscostoids (ACIP 1098), (Grade Al\n\nRecent evidonee Indicates that high doses of immunoglobuins can\nInst‘ invmane response to moasion and ruse vacone for 3\nmons or more. nd Nonce, MMR vmmunisabon shou be delayed\n(ACIP 1998) (Grade A",
            "extraction_method": "ocr"
        },
        {
            "page_number": 33,
            "text": "REFERENCES\n\n1. Academy of Medicine of Malaysia 2001 Maiysian immunisation\nManual, Cologe of Pacdatics\n\n2. American Academy of Paediatr: pickering Lk, 2d 2000 Rea\n‘Book: Report ot the cometoo on infectious Diseaeas 25° 08. ER\nGrove Vitae.\n\n3 Bakshi SS, cooper Lz (1090) Rubella and mumps vaccine. Pood\n(Cla Nm. 373), pp 691-67\n\n4 Bara LI. Sholds WD & Bockwth L (1983) infants and edron\nwh convulsions and hypotonic hyporesponsive epeodes flowing\n‘ohthera-ttonie pers immuniston, Palace, $1, 99 78S.\n708\n\n5S. Bat Ki, Lin KF, (1990) Vaccine. preventable. dase. and\nImunisason inthe Sevelping world Pedow Cin M Am, 373) PP\nToetse\n\n{6 Blsgard KM eta (2000) Diptnheria vaccine afectvenes: A case\n‘onl! study im Russi. Journal of fectiousdsoase, 181 (supp),\npps 166-187\n\n7. Contes or Disease Conte (1991) Dptheris, totus, and porta:\nrocommendatons fr vacene ws and otter provenive mossires-\nrecommendatcn of ho Imunsavon racten Aawnary Commnton\n(ACIP) ANav 40 (ro. FFE 10).\n\n8 Centers for Dsoase Corl (1996) Update Vaccine Side Ect\n‘averse Reactons Contandatone and’ Precautions\n‘Recommendatons of the Advisory Committes on Inmunisation\nProctons (ACIP) MMR. 48 R12. 1.38\n\n8. Chan Reta (2000) Uieano 1982: Fst assossment of iphtharia\nvaccine affectvoness during the recent osurgonce of aphihaia\nthe former sowel uso, ourna of inectous disses, 18( spp 1),\npps 178-165,\n\n10, Gimaz R, Mons! C, Angulo E, Fanta E, tone V, Blase LR,\n{GaroliV, Zanoti AR (2001) Safty aed immunogenicity of 2\n‘conjugn vacane against Hawmophius iniuenzae ype b capsular\npolysocchaidetotanus vaccinaton related ob numbor of\n‘osos administration. J nie Dis, 1812) Jun 15, pp 1810-21\n\n11, Cody Ci Bara LJ & Cheny JD (198%) Notre and rates of adverse\n‘eacons with OTP and DT immunisation i iat and care,\nPediat, 68, pp 630-060\n\n12 Cowan LD, Grif MR, Howson CP & Kate M (1093) Acute\n‘encechslopahy und chronic neurckogical damage aller petusist\nvaccine. Vaccin, 11 (14) Nov, pp 1371-9\n\n13, De Serres G,Boulane N, Owval8 et a, (1906) Effectiveness of\nwhole call partes vaccine child care centes and schools\nedit infct Dis J, 15(6). Jun, pp 510-24",
            "extraction_method": "ocr"
        },
        {
            "page_number": 34,
            "text": "15,\n16.\n\nw.\n‘2.\n19.\n\nEa\n\n2\n\n2.\n\n2\n\nEa\n\n‘eBiasa RL Daley MF, Simoes EAF (2002) Immunisation. (Curent\nPediat icgnoss And Treatment)\n\nDeparment of Health, nied Kingdom (1996) tmmenisation\n‘against infectious isease (\"The Gren Book): WMISO.\n\nEdwarss KM Meade BD, Decker Nd ta, (1995) Comparison of\n13 acobulor pertussis vaclnes: overt and sarlogc response\nedits, 86 (9 pt 2), 546-5?\n\nFronkal LO (1900) Ravine immunsation for American chien in\n‘he 1990s. Ped CHAN Am, 37(9). pp 531-547\n\nForos J, Conroras G, (1990) Vaccine latod murs meningiis~\nCanada. Can Dis Why Rop. 1680), Dac 15, pp 283-4\n\nGatarka AML (1993), Tho. mmunciogies! bass for immunisation\nSoros: Mode 2 Diptera, WHOFEPger 0.13.\n\nGalazka AM (1993) Tho nmundogia! bass for immonisaton\n‘ovioe: Module 3-Totanus, WHIOTEPUgeN 00.13,\n\nGallo G, Cet Dogt tM, Cerquet M, Plovesan C. Tozzi AE,\n‘Salmaso S 2002} pet of aegioal Hb vaccination programme\n{ntaly. Vaccine, 27), Jan 15, pp 2985\n\n‘Gib 0, Spout V, Giscomat A. Gifts H, Masters J, Msbah S,\nNokes L, Pagharo'A, Gaqurto Krol 8, eta. (1096) Anlbody\n\n‘Gib 0, Gacomell A Master 3, Spouou V, Rupa E. Gafihs H\n‘rol & Giaqunto C, Goiabiat 0. (1998) Persstonce of anibody\n‘esponses to Haemophilus infuonzae’ type b polysaccharide\n‘conjugate vaccine. in chilean ‘ath vorcaty ccuived human\n‘ewmunadescioney virus infocton. Pediat infect Dis J 1512) Dae.\n5p 1097-105,\n\n{Guttsson t, Halnder HO, Ot pat al, (1996) A controled Wil ot\ntwo senor vaccines and one wholo-ol vacone against pertussis\nEngl Med, 934) Feb 8, pp 341-8\n\nKeistorson_K ($998) Vaccination of splenactomised chile,\nSntbedy response to Haomaphis Intuonzae type D conjupao\n‘coin, Upesks Laoger, 1552), Jan 10, pp 1873\n\n{oteina 8, Hiarchote A Simasathian 5 (2001) Salty and\nImmunogen of combined or associated administration of PRP-T\n‘cone wah dphtvera, tefnus and pertuse vaccine In. Thal\nhlsren. J Top Pediat 471), Feb, pp 269,\n\n‘Mas SA, Petoeson K. Koos Mt, Huebner RE, Mba N. Moshupi\nR Saloon H. Crowe Brown 1. Klugman KP (2002) Reduood\n‘ffectvonmss of Haomphis infuenzae type © conugate vaccine\nIn enadron wth a igh previo of human immunodetency wast\ntype tintoctn, Peay Infect Dis 218), Ap. pp 315-21",
            "extraction_method": "ocr"
        },
        {
            "page_number": 35,
            "text": "sins mma\n\nMadson KM, Hid A, Vestorgaard M, Schondel D, Wola J\n‘Thorson P, Olan J, Maye M (2002) MMR vacenalion and\nauism=2 population-based folow-up sudy] Ugeskr Laager\nfeuds) Dec 2 pps7aid\n\nMePhiles Marcuse EK. (2001) Vaccine Safely. Curr Probl\nPedi 31(8) Agr, pp 01-21\n\nger, Maage'N, Diamond J, Wadsworth J. Rose € (1999)\nPertsisimmuniston and sotaus sete neurolegical anoseags In\nhadron. BM 3076919). Nov 8. pp 1171-8\n\nMistry of Health Malaysia (2002) Chidhood Immunisaton. Healt\nTectnlogy Assasamont\n\nMMWR “Use of Diptera Toxod-Tetanus Toxoid-Acelar\nPertussis Voccio as a Fvv-Doso Sarios. Novembert7, 2000 7\n45RR13) 18\n\nMoridty.& Mortaity Wookly Roper. (1906) Progress. foword\n‘olomyats eradicaton People's Repubie of China, 1990-1996,\n44940) op 1076-9\n\nMatidiy & Mortatly Weekly Report. (1987) Progress foward\nolomyatseraicaton Aca, 45 (15, pp 321.5\n\nMotidty & Moray Woely Report. (1888) impact of sequent\nIPVIOPY schedule on vaccination coverage levels Unied Sato 7\n(a7 pp 10179\n\nNNatonal Heath and Medical Resoarsh Counct, Austata, (1997)\n‘astraton Immunisation hand book © ndon\n\nPetors VB Sood SK (1096) Immunity to Haomephits inoenzae\nype b polysaccharge capsule ator vaccination wth the complote\nnos of oigosaccharide CRMIG7 conga vocine infants wth\nhuman immunodeficency virus infecton. J Poa 28(3), Mae,\npp 0005.\n\nRamsay MEB, Rao M. Begg NT ot al,(1098) Antibody response to\n‘accelerated inmunision wih dphthera, atanus, parssie vaccine.\nneat 2 pp 208\n\nFReod 15, Frasch CE, Rich K, Fitzgerald GA, Clemons JO, Pit\nPetion Si, Hanson 1C, Handelsman €. Ola ©, Fowior MG. (1998)\n‘The immunogenicity of Haomephius influenzae typo b conto\n‘vaccine i earn born o human mamunodoticenty veut’\nwomen, Woman and infants Transmission Stody Group. Pedr\nInet Dis J 178), May, pp 30-7\n\nFRennls MB, Englund JA. Borstoin Ol, Losonsty GA, Anderson\nEL Picichoro ME, Munoz FM, Wolf MC. (2000) Dimnuton ofthe\n‘ani-pohrbosyibil phosphate response io a combined diphhera\n\\elanus aco petusisMaemophius infuenzae type b vacrine\nby concarront activated polown vaccination, Pea Inect Die\n195), May, pp $17.23.",
            "extraction_method": "ocr"
        },
        {
            "page_number": 36,
            "text": "an\n\n4%\n\n49,\n46,\n\na\n\n48\n\n40,\n\nst\n\nutstin RM. Rudy BJ, Caan A. (1996) Response of human\nlmiurodefeiency \"vrus-exposed and. -ifeciod infants 10\nHaomophis infuenzae type b conlugate vaccine. Arch Pedr\n‘Adolse Med. 150), ug, pp 838-4\n\nSedaghatian MR, et a1986) Backs Calmote Guerin vaccination\nin rotor nfs: In J Tubere Lng 0i8.2 (8), No, pp 670.82,\nTaylor B. Miler E. Uingam R. Andrews N, Sinmos A, Stowe J.\n(2002) “Measles, mumps, and rubela vaconation and bowel\n‘roblems cr developmental regression incadren with aus\nPopulation study. BN. 324 (7394). Feb, pp 383-6,\n\nTheo Austratan Collage of Paodatics Pay Statement. (1094)\nCContaindcatons to krmunsaton agaist pertussis. J Paedsir\nhia Homi. 30), 4p. pp 310-1\n\n‘Tanion ON & Hanlon M(2000) Coctrane Database Systomatic\nReview (2):CO 001478\n\n‘tok CR otal (1990) isk of dipthana among shook in\n‘tho Russion Federation in relation to fine sc lat vacinatin\nTho Lancet, 383, aN 30, pp 385358\n\n|WHO (1095) Factors aflocing tho immunogenicity of cral polo\nvaccina: a prospective evaluation in Brazl and Gambia, Wor\noath Organisation Cotaboraton Study Grovp on Oral Polowus\n‘ccine, Journal of Infectious Disease 1715), p 1097-105 |\n\nWHO\" (1997) Combined” immunisation of infants wil orl\nInacivated pooveus vaccines: sults ofa Yandorisd tain tho\nGambia, Omen and Thaland: WHO Cotaborston Stay Group on\n‘ral and inatvated Poliowus Vaccnes, sou of lectus\nDivoose, 175 (spp), 5p 8 215-27\n\n\\WHO (1988) Genova’ Global oradcaton of polonyolis by tho\n‘ear 2000 Word Woah Ascomtly Rosch WHA 41.28)\n\n{WHO Expanded Program on immunisaton. Inmunsation Poy\nWHOEPIGENEA7\n\n{WHO “Expanded Program on Immunisaton. kxmusalon Potcy\nWHOEPIGENTS 03\n\n{WHO Immunization pokey (1905). Globe programme for vaccines\n‘and immunisation WHOFEPUGENIS.3\n\n“Zimmerman 8, Gold R. Lavi 8 (1987) Immurisaton. Prtaduato\nMedicine, 82,8): 112-7",
            "extraction_method": "ocr"
        }
    ]
}